Skip to main content

Breast Cancer Research and Treatment

Ausgabe 2/2015

Inhalt (25 Artikel)

Open Access Review

The effect of immediate breast reconstruction on the timing of adjuvant chemotherapy: a systematic review

J. Xavier Harmeling, Casimir A. E. Kouwenberg, Eveline Bijlard, Koert N. J. Burger, Agnes Jager, Marc A. M. Mureau

Review

Advancing breast cancer survivorship among African-American women

Steven S. Coughlin, Wonsuk Yoo, Mary S. Whitehead, Selina A. Smith

Preclinical study

RNAi-mediated silencing of Anxa2 inhibits breast cancer cell proliferation by downregulating cyclin D1 in STAT3-dependent pathway

Fei Zhang, Zhiyong Wang, Jie Yuan, Xiyin Wei, Ran Tian, Ruifang Niu

Preclinical study

Bilateral breast cancer, synchronous and metachronous; differences and outcome

J. J. Jobsen, J. van der Palen, F. Ong, S. Riemersma, H. Struikmans

Open Access Preclinical study

TMEM33: a new stress-inducible endoplasmic reticulum transmembrane protein and modulator of the unfolded protein response signaling

Isamu Sakabe, Rong Hu, Lu Jin, Robert Clarke, Usha N. Kasid

Preclinical study

Imaging breast cancer morphology using probe-based confocal laser endomicroscopy: towards a real-time intraoperative imaging tool for cavity scanning

Tou Pin Chang, Daniel R. Leff, Sami Shousha, Dimitri J. Hadjiminas, Rathi Ramakrishnan, Michael R. Hughes, Guang-Zhong Yang, Ara Darzi

Preclinical study

Developing in vitro models of human ductal carcinoma in situ from primary tissue explants

Daniel D. Brown, David J. Dabbs, Adrian V. Lee, Kandace P. McGuire, Gretchen M. Ahrendt, Rohit Bhargava, Nancy E. Davidson, Adam M. Brufsky, Ronald R. Johnson, Steffi Oesterreich, Priscilla F. McAuliffe

Preclinical Study

Adipocytes can induce epithelial-mesenchymal transition in breast cancer cells

YuKyung Lee, Woo Hee Jung, Ja Seung Koo

Clinical trial

Long-term objective esthetic outcome after breast-conserving therapy

André Hennigs, Benjamin Hartmann, Geraldine Rauch, Michael Golatta, Patrik Tabatabai, Christoph Domschke, Sarah Schott, Florian Schütz, Christof Sohn, Joerg Heil

Clinical Trial

Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29

Judith-Anne W. Chapman, Joseph P. Costantino, Bin Dong, Richard G. Margolese, Kathleen I. Pritchard, Lois E. Shepherd, Karen A. Gelmon, Norman Wolmark, Michael N. Pollak

Clinical trial

Metformin intervention in obese non-diabetic patients with breast cancer: phase II randomized, double-blind, placebo-controlled trial

Kwang-Pil Ko, Seung Hyun Ma, Jae-Jeong Yang, Yunji Hwang, Choonghyun Ahn, Young-Min Cho, Dong-Young Noh, Byung-Joo Park, Wonshik Han, Sue K. Park

Clinical trial

Supervised physical exercise improves VO2max, quality of life, and health in early stage breast cancer patients: a randomized controlled trial

Soraya Casla, Sara López-Tarruella, Yolanda Jerez, Iván Marquez-Rodas, Daniel A. Galvão, Robert U. Newton, Ricardo Cubedo, Isabel Calvo, Javier Sampedro, Rubén Barakat, Miguel Martín

Clinical trial

High-throughput pharmacogenetics identifies SLCO1A2 polymorphisms as candidates to elucidate the risk of febrile neutropenia in the breast cancer RAPP-01 trial

Céline Callens, Marc Debled, Marc Delord, Isabelle Turbiez-Stalain, Corinne Veyret, Ivan Bièche, Etienne Brain

Epidemiology

Impact of disease management programs on women with breast cancer in Germany

Louis Jacob, Peyman Hadji, Ute-Susann Albert, Matthias Kalder, Karel Kostev

Epidemiology

Complex fibroadenoma and breast cancer risk: a Mayo Clinic Benign Breast Disease Cohort Study

Aziza Nassar, Daniel W. Visscher, Amy C. Degnim, Ryan D. Frank, Robert A. Vierkant, Marlene Frost, Derek C. Radisky, Celine M. Vachon, Ruth A. Kraft, Lynn C. Hartmann, Karthik Ghosh

Epidemiology

The effects of erythropoiesis-stimulating agents on the short-term and long-term survivals in metastatic breast cancer patients receiving chemotherapy: a SEER population-based study

Yinzhi Lai, Zhong Ye, Jesse M. Civan, Chun Wang, Massimo Cristofanilli, Zhaomei Mu, Laura Austin, Juan P. Palazzo, Ronald E. Myers, Hushan Yang

Epidemiology

Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy

Misbat Chaudry, Xiudong Lei, Ana M. Gonzalez-Angulo, Elizabeth A. Mittendorf, Vicente Valero, Debu Tripathy, Gabriel N. Hortobagyi, Mariana Chavez-MacGregor

Epidemiology

Metabolic syndrome, insulin resistance, and mammographic density in pre- and postmenopausal women

Bo-Kyoung Kim, Yoosoo Chang, Jiin Ahn, Hyun-Suk Jung, Chan-Won Kim, Kyung Eun Yun, Min-Jung Kwon, Byung-Seong Suh, Eun Chul Chung, Hocheol Shin, Seungho Ryu

Open Access Epidemiology

Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy

Marissa S. Ellingson, Steven N. Hart, Krishna R. Kalari, Vera Suman, Kimberly A. Schahl, Travis J. Dockter, Sara J. Felten, Jason P. Sinnwell, Kevin J. Thompson, Xiaojia Tang, Peter T. Vedell, Poulami Barman, Hugues Sicotte, Jeanette E. Eckel-Passow, Donald W. Northfelt, Richard J. Gray, Sarah A. McLaughlin, Alvaro Moreno-Aspitia, James N. Ingle, Ann M. Moyer, Daniel W. Visscher, Katie Jones, Amy Conners, Michelle McDonough, Eric D. Wieben, Liewei Wang, Richard Weinshilboum, Judy C. Boughey, Matthew P. Goetz

Epidemiology

Candidate early detection protein biomarkers for ER+/PR+ invasive ductal breast carcinoma identified using pre-clinical plasma from the WHI observational study

Matthew F. Buas, Jung-hyun Rho, Xiaoyu Chai, Yuzheng Zhang, Paul D. Lampe, Christopher I. Li

Brief Report

Breast cancer screening in the era of density notification legislation: summary of 2014 Massachusetts experience and suggestion of an evidence-based management algorithm by multi-disciplinary expert panel

Phoebe E. Freer, Priscilla J. Slanetz, Jennifer S. Haas, Nadine M. Tung, Kevin S. Hughes, Katrina Armstrong, A. Alan Semine, Susan L. Troyan, Robyn L. Birdwell

Brief Report

FOXA2 mRNA expression is associated with relapse in patients with Triple-Negative/Basal-like breast carcinoma

Ariadna Perez-Balaguer, Fernando Ortiz-Martínez, Araceli García-Martínez, Critina Pomares-Navarro, Enrique Lerma, Gloria Peiró

Letter to the Editor

Brief screening of patients with distressing fear of recurrence in breast cancer survivors

Tatsuo Akechi, Kanae Momino, Hiroji Iwata

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.